BEAM Beam Therapeutics Inc.

8-K Current Report

Filed: March 5, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Beam Therapeutics Inc. (BEAM) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 1.02: Termination of a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.02 · Termination of a Material Definitive Agreement

• Bio Palette License Agreement terminated March 2, 2026 due to Bio Palette's planned dissolution — no future payments owed by either party
• Continuity secured: Kobe University standby license (signed Feb 9, 2026) activated, preserving BEAM's exclusive base editing patent rights

+3 more insights

Other Beam Therapeutics Inc. 8-K Filings

8-K Feb 24, 2026

Get deeper insights on Beam Therapeutics Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.